“Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study”, J of Skin, vol. 2, no. S1, p. S20, Feb. 2018, doi: 10.25251/skin.2.supp.20.